Walleye Capital LLC Intra Cellular Therapies, Inc. Put Options Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $901,180 - $1.06 Million	-14,000 Reduced 97.22%	400 $27,000
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $5,209 - $6,409	100 Added 0.7%	14,400 $750,000
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $716,177 - $870,364	13,100 Added 1091.67%	14,300 $905,000
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $459,899 - $598,395	-10,500 Reduced 89.74%	1,200 $64,000
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $17,628 - $21,780	-400 Reduced 3.31%	11,700 $619,000

Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $516,670 - $725,879	12,100 New	12,100 $563,000
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $774,299 - $2.08 Million	-62,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $285,318 - $1.51 Million	39,300 Added 166.53%	62,900 $2.16 Million
Q3 2019 Nov 14, 2019	BUY	$7.47 - $14.03 $176,292 - $331,108	23,600 New	23,600 $176,000
Q2 2019 Aug 14, 2019	SELL	$10.65 - $14.29 $36,210 - $48,586	-3,400 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $37,060 - $47,906	3,400 New	3,400 $41,000

381

77.7M

1.7M

1.13M

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.47B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.